Hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Performance Status 0 or 1 (ECOG) 2. Child-Pugh class A (score 5 or 6) 3. No past history of molecular targeting drugs including treatment of the other cancers. 4. Laboratory data fulfills all criteria as below 1) neutrophil count more than 1.5x109 /L 2) Hemogblobin more than 8.5 g/dL 3) Total bilirubin less than 2.0 mg/dL 4) Blood pressure less than 150/90 mmHg
Exclusion criteria
Exclusion criteria: 1. Patients regarded as inappropriate subject 2. Patients who lack of ability of judgement, despite fulfill the listed above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To clarify the relationship between the exposure of lenvatinib at the start of treatment and two week from the start of treatment and the gene polymorphisms of p-glycoprotein and breast cancer resistant protein. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To clarify the relationship between the exposure of lenvatinib and the clinical response 2)To examine relationship between plasma and urinary carnitine levels and extent of fatigue | — |
Countries
Japan
Contacts
Juntendo University Nerima Hospital Department of Gastroenterology